Please be informed that the Board of Directors of the Company, at its meeting held today i.e. 4th May, 2026, inter-alia, has approved: i. the Audited Financial Results and Financial Statements ....
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.1 pts more than Nifty Smallcap 250 and 8.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wockhardt Ltd reported strong FY2026 results with standalone revenue growing 24% to Rs 1,739 crore (FY25: Rs 1,402 crore) and PAT turning around from a loss of Rs 12 crore to a profit of Rs 317 crore. Consolidated revenue was Rs 3,373 crore (FY25: Rs 3,012 crore) with PAT of Rs 213 crore versus a loss of Rs 47 crore in the prior year. Exceptional items include a Rs 110 crore charge for deconsolidation of US subsidiaries (Wockhardt USA LLC and Morton Grove Pharmaceuticals Inc. filed for Chapter 7 bankruptcy in July 2025), a Rs 35 crore gain from settlement of the Dr. Reddy's Laboratories legal dispute, and a Rs 10 crore charge for new labour codes impact — net charge of Rs 85 crore on consolidated. Cash flow from operations was positive at Rs 241 crore (standalone) and Rs 390 crore (consolidated), compared to negative operating cashflows in the prior year. The board also approved a proposal to raise funds via equity or securities, subject to shareholder approval. Auditors MSKC & Associates LLP issued an unmodified (clean) opinion.
Strong turnaround in profitability with 24% revenue growth and cash flow improvement. However, the US business exit created significant exceptional charges. The fund-raising proposal may dilute equity but signals capital needs for growth or debt management.